TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, and is plagued by a paucity of targeted treatment options and tumour resistance to chemotherapeutics. The causal link between chronic inflammation and PDAC suggests that molecular regulators of the immune system promote disease...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene Jg. 40; H. 41; S. 6007 - 6022
Hauptverfasser:	Lundy, Joanne, Gearing, Linden J., Gao, Hugh, West, Alison C., McLeod, Louise, Deswaerte, Virginie, Yu, Liang, Porazinski, Sean, Pajic, Marina, Hertzog, Paul J., Croagh, Daniel, Jenkins, Brendan J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 14.10.2021 Nature Publishing Group
Schlagworte:	38/1 38/23 38/39 38/77 38/91 45 631/250/262 631/67/1059/2326 631/67/1059/602 631/67/1504/1713 64/60 82/51 Adenocarcinoma Animals Apoptosis Biopsy Cancer Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Care and treatment Cell Biology Cell Growth Processes - drug effects Cell Growth Processes - physiology Cell Line, Tumor Cellular signal transduction Chemoresistance Chemotherapy Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Female Gemcitabine Genetic aspects Health aspects Human Genetics Humans Immune system Internal Medicine Medical prognosis Medicine Medicine & Public Health Mice Mice, Inbred BALB C Mice, Inbred NOD Molecular Targeted Therapy Oncology Pancreas Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pancreatic tumors Patient outcomes Patients Precision medicine Prognosis Survival Survival Analysis Therapeutic targets TLR2 TLR2 protein Toll-Like Receptor 2 - antagonists & inhibitors Toll-Like Receptor 2 - metabolism Toll-like receptors Transcriptomes Tumors Xenograft Model Antitumor Assays Xenografts Australia
ISSN:	0950-9232, 1476-5594, 1476-5594
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!